Alembic Pharmaceuticals Limited
Simbol: APLLTD.NS
NSE
990.3
INRTržna cena danes
33.3489
Razmerje P/E
0.6374
Razmerje PEG
194.66B
Kapaciteta MRK
- 0.01%
Donos DIV
Alembic Pharmaceuticals Limited (APLLTD-NS) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4739.2 | 921.2 | 610.9 | 2850.3 | |||||||||||||
balance-sheet.row.short-term-investments | 4804.2 | 166.4 | 316.2 | 1869.7 | |||||||||||||
balance-sheet.row.net-receivables | 22766.1 | 11291.1 | 11900.1 | 8067.3 | |||||||||||||
balance-sheet.row.inventory | 30145.1 | 14752.7 | 16097 | 14861.5 | |||||||||||||
balance-sheet.row.other-current-assets | 5023.9 | 2135.2 | -0.1 | -0.1 | |||||||||||||
balance-sheet.row.total-current-assets | 62674.3 | 29100.2 | 28607.9 | 25779 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 60805.5 | 29997.3 | 39472.6 | 36480.3 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 1548.2 | 3229.5 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 172.2 | 0 | 1548.2 | 3229.5 | |||||||||||||
balance-sheet.row.long-term-investments | 1769.2 | 963.3 | 1184 | 493.1 | |||||||||||||
balance-sheet.row.tax-assets | 2467.1 | 1230.1 | 58.8 | 1108 | |||||||||||||
balance-sheet.row.other-non-current-assets | -1507.4 | 537.4 | 348.8 | -0.1 | |||||||||||||
balance-sheet.row.total-non-current-assets | 63706.6 | 32728.1 | 42612.4 | 41310.8 | |||||||||||||
balance-sheet.row.other-assets | 0.1 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 126381 | 61828.3 | 71220.3 | 67089.8 | |||||||||||||
balance-sheet.row.account-payables | 14417.6 | 6798.1 | 7063.9 | 6687.7 | |||||||||||||
balance-sheet.row.short-term-debt | 14541.5 | 6527.9 | 6449.7 | 3121.8 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 21.5 | |||||||||||||
balance-sheet.row.long-term-debt-total | 1366.4 | 692.3 | 721.4 | 2714.3 | |||||||||||||
Deferred Revenue Non Current | -831.4 | -831.4 | -1976.9 | 855.2 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 831.4 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 1623.4 | 855.4 | -0.1 | 0.2 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3507.8 | 1754.3 | 1679.5 | 3611.7 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 1705.4 | 861.5 | 871.2 | 838.2 | |||||||||||||
balance-sheet.row.total-liab | 37976.2 | 18123.6 | 18844.8 | 16420.1 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 786.2 | 393.1 | 393.1 | 393.1 | |||||||||||||
balance-sheet.row.retained-earnings | 35684.4 | 35684.4 | 25543.9 | 24241 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 133047.2 | 335.4 | 18808.8 | 18513.8 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 7291.8 | 7291.8 | 7629.7 | 8128.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 176809.6 | 43704.7 | 52375.5 | 51276.1 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 214785.8 | 61828.3 | 71220.3 | 67089.8 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | -606.4 | |||||||||||||
balance-sheet.row.total-equity | 176809.6 | 43704.7 | 52375.5 | 50669.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 214785.8 | - | - | - | |||||||||||||
Total Investments | 6407 | 963.3 | 1184 | 493.1 | |||||||||||||
balance-sheet.row.total-debt | 15907.9 | 7220.2 | 7171.1 | 5836.1 | |||||||||||||
balance-sheet.row.net-debt | 15972.9 | 6465.4 | 6560.2 | 4855.5 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 5902.1 | 3545.9 | 6201.1 | 13680.8 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 2773.1 | 2754.3 | 2867.8 | 1834.7 | |||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.change-in-working-capital | 0 | -575.6 | -3673.4 | 2395.4 | |||||||||||||
cash-flows.row.account-receivables | 0 | -2228.8 | -4696.2 | 5109.3 | |||||||||||||
cash-flows.row.inventory | 0 | 1344.4 | -1235.5 | -2986.2 | |||||||||||||
cash-flows.row.account-payables | 0 | -281.7 | 366.7 | 452.7 | |||||||||||||
cash-flows.row.other-working-capital | 0 | 590.5 | 1891.6 | -180.4 | |||||||||||||
cash-flows.row.other-non-cash-items | -5902.1 | 1514.9 | 128 | -3277.1 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 5546.2 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -4434.1 | -4256.4 | -6595.1 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | 18.7 | 46.1 | -4.6 | |||||||||||||
cash-flows.row.purchases-of-investments | 0 | -70 | -1392.9 | -1861 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | -18.7 | 1869.7 | 1861 | |||||||||||||
cash-flows.row.other-investing-activites | 0 | 28.2 | 13.8 | -1788.4 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4475.9 | -3719.7 | -8388.1 | |||||||||||||
cash-flows.row.debt-repayment | 0 | -2000 | -3000 | -3792.7 | |||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 7340.8 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | -1965.6 | -2751.9 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 0 | 1346 | 3578.4 | -9522.4 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -2619.6 | -2173.5 | -5974.3 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | -9.3 | |||||||||||||
cash-flows.row.net-change-in-cash | 5546.2 | 143.9 | -369.7 | 262.2 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 7314 | 754.8 | 610.9 | 980.6 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1767.8 | 610.9 | 980.6 | 718.4 | |||||||||||||
cash-flows.row.operating-cash-flow | 5546.2 | 7239.5 | 5523.5 | 14633.8 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | -4434.1 | -4256.4 | -6595.1 | |||||||||||||
cash-flows.row.free-cash-flow | 5546.2 | 2805.4 | 1267.1 | 8038.7 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 61181 | 56526.2 | 52317.9 | 52762.2 | |||||||||||||
income-statement-row.row.cost-of-revenue | 17682.1 | 17088.2 | 17231.9 | 15212.7 | |||||||||||||
income-statement-row.row.gross-profit | 43498.9 | 39438 | 35086 | 37549.5 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 4785.4 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 255.9 | 27.4 | 1.3 | 2 | |||||||||||||
income-statement-row.row.operating-expenses | 37416.9 | 35108.9 | 29160 | 24581.1 | |||||||||||||
income-statement-row.row.cost-and-expenses | 55099 | 52197.1 | 46391.9 | 39793.8 | |||||||||||||
income-statement-row.row.interest-income | 0 | 3.3 | 17.3 | 15.8 | |||||||||||||
income-statement-row.row.interest-expense | 596.2 | 501.7 | 177.3 | 160.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -479.9 | -831.8 | 379.3 | 1029.8 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 255.9 | 27.4 | 1.3 | 2 | |||||||||||||
income-statement-row.row.total-operating-expenses | -479.9 | -831.8 | 379.3 | 1029.8 | |||||||||||||
income-statement-row.row.interest-expense | 596.2 | 501.7 | 177.3 | 160.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 2773.1 | 2754.3 | 2867.8 | 1834.7 | |||||||||||||
income-statement-row.row.ebitda-caps | 9020.8 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | 6131.3 | 4377.8 | 5874.7 | 12968.4 | |||||||||||||
income-statement-row.row.income-before-tax | 5651.5 | 3545.9 | 6201.1 | 13680.8 | |||||||||||||
income-statement-row.row.income-tax-expense | -250.6 | 126.1 | 1044.6 | 2533.2 | |||||||||||||
income-statement-row.row.net-income | 5902.1 | 3419.9 | 5209.4 | 11465 |
Pogosto zastavljeno vprašanje
Kaj je Alembic Pharmaceuticals Limited (APLLTD.NS) skupna sredstva?
Alembic Pharmaceuticals Limited (APLLTD.NS) skupna sredstva so 61828300000.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so 32255000000.000.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.711.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je 28.216.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je 0.096.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so 0.100.
Kaj je Alembic Pharmaceuticals Limited (APLLTD.NS) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je 3419900000.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 7220200000.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 35108900000.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so -1478000000.000.